Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients

Journal of the American College of Cardiology

Volumn 40, Issue 10, 2002, Pages 1777-1785

  Allen Maycock, Chloe A ^a   Muhlestein, Joseph B ^a,b   Horne, Benjamin D ^a   Carlquist, John F ^a,b   Bair, Tami L ^a   Pearson, Robert R ^a   Li, Qunyu ^a   Anderson, Jeffrey L ^a,b  

^a LDS HOSPITAL   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GERIATRIC PATIENT; HUMAN; ISCHEMIC HEART DISEASE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RISK MANAGEMENT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; COHORT STUDIES; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0037145887     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)02477-4     Document Type: Article

References (21)

1. American Heart Association. 2002 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association, 2002.
2. Anonymous. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
3. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
4. Sacks FM, Pfeffer MA, Moye LA, et al, the Cholesterol And Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
5. Horne BD, Muhlestein JB, Carlquist JF, et al. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. J Am Coll Cardiol 2000;36:1774-80.
6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 20,536 high-risk individuals: A randomized placebo-controlled trial. Lancet 2002;360:7-22.
7. Miettinen TA, Pyorala K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: Findings from the Scandinavian Simvastatin Survival Study (4S) (see comments). Circulation 1997;96:4211-8.
8. Hunt D, Young P, Simes J, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial. Ann Intern Med 2001;134:931-40.
9. Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range: Results of the Cholesterol And Recurrent Events (CARE) trial. Ann Intern Med 1998;129:681-9.
10. Shepherd J, Cobbe SM, Ford I, et al., the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
11. Manolio TA, Pearson TA, Wenger NK, et al. Cholesterol and heart disease in older persons and women: Review of an NHLBI workshop. Ann Epidemiol 1992;2:161-76.
12. Schatz IJ, Masaki K, Yano K, Chen R, Rodriguez BL, Curb JD. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: A cohort study. Lancet 2001;358:351-5.
13. Massing MW, Sueta CA, Chowdhury M, Biggs DP, Simpson RJ Jr. Lipid management among coronary artery disease patients with diabetes mellitus or advanced age. Am J Cardiol 2001;87:646-9.
14. Muhlestein JB, Horne BD, Carlquist JF, et al. Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease. Circulation 2000;102:1917-23.
15. Taylor GS, Muhlestein JB, Wagner GS, et al. Implementation of a computerized cardiovascular information system in a private hospital setting. Am Heart J 1998;136:792-803.
16. Anonymous. Myocardial infarction and mortality in the Coronary Artery Surgery Study (CASS) randomized trial. N Engl J Med 1984;310:750-8.
17. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease (see comments) (erratum appears in J Card Fail 1998;4:367). J Card Fail 1997;3:249-54.
18. Byington RP, Davis BR, Plehn JF, et al. Reduction of stroke events with pravastatin: The Prospective Pravastatin Pooling (PPP) Project. Circulation 2001;103:387-92.
19. Ferguson J III. Meeting highlights: American Heart Association Scientific Sessions 2001. Circulation 2002;105:E37-41.
20. Muhlestein JB, Horne BD, Bair TL, et al. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol 2001;87:257-61.
21. Shepherd J, Blauw GJ, Murphy MB, et al., the PROSPER Study Group. The design of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Am J Cardiol 1999;84:1192-7.